Sale Leasebacks as a Funding Strategy for Biomanufacturers

This technical report discusses the increasing relevance of sale leasebacks as a funding strategy for biomanufacturers facing capital constraints in 2025. It outlines the current challenges within the biopharmaceutical industry, including regulatory requirements, high research and development costs, and the cautious lending environment. The report explains how sale leasebacks can serve as a strategic alternative for raising capital, allowing companies to sell their real estate and lease it back, thus unlocking the full value of their properties. It details the benefits of this approach, including the ability to fund growth initiatives without diluting equity. The report also addresses common misconceptions regarding the complexity and implications of long-term lease obligations, emphasizing that well-negotiated agreements can maintain operational control and strategic flexibility. Several case studies illustrate successful sale leaseback transactions, highlighting their effectiveness in providing immediate cash for critical investments in the biomanufacturing sector.